1870 related articles for article (PubMed ID: 27018978)
1. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
3. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
4. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
5. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
[TBL] [Abstract][Full Text] [Related]
6. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
7. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
Van der Perren A; Toelen J; Casteels C; Macchi F; Van Rompuy AS; Sarre S; Casadei N; Nuber S; Himmelreich U; Osorio Garcia MI; Michotte Y; D'Hooge R; Bormans G; Van Laere K; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
Neurobiol Aging; 2015 Mar; 36(3):1543-58. PubMed ID: 25599874
[TBL] [Abstract][Full Text] [Related]
9. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
12. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
Ulusoy A; Decressac M; Kirik D; Björklund A
Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871
[TBL] [Abstract][Full Text] [Related]
13. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.
Febbraro F; Sahin G; Farran A; Soares S; Jensen PH; Kirik D; Romero-Ramos M
Neurobiol Dis; 2013 Aug; 56():47-58. PubMed ID: 23567651
[TBL] [Abstract][Full Text] [Related]
14. α-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.
Cooper JF; Spielbauer KK; Senchuk MM; Nadarajan S; Colaiácovo MP; Van Raamsdonk JM
Exp Neurol; 2018 Dec; 310():58-69. PubMed ID: 30194957
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of alpha-synuclein neurodegeneration.
Waxman EA; Giasson BI
Biochim Biophys Acta; 2009 Jul; 1792(7):616-24. PubMed ID: 18955133
[TBL] [Abstract][Full Text] [Related]
16. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants and animal models in SNCA and Parkinson disease.
Deng H; Yuan L
Ageing Res Rev; 2014 May; 15():161-76. PubMed ID: 24768741
[TBL] [Abstract][Full Text] [Related]
18. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
Bickle L; Hopwood JJ; Karageorgos L
Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442
[TBL] [Abstract][Full Text] [Related]
19. Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons.
Aldrin-Kirk P; Davidsson M; Holmqvist S; Li JY; Björklund T
PLoS One; 2014; 9(7):e100869. PubMed ID: 24999658
[TBL] [Abstract][Full Text] [Related]
20. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]